REPLIGEN CORP acquired FlexBiosys, Inc. for ~$41.0 million total ($29.0M cash + Repligen stock, plus earnouts), a transaction completed in April 2023, structured as combination (cash plus stock) with earnouts.
FlexBiosys, Inc. operates in Fluid Management, is based in Branchburg, New Jersey, USA. Acquisition of all outstanding equity interests in FlexBiosys, Inc., a custom designer and manufacturer of single-use bioprocessing products, strengthening Repligen's fluid-management portfolio. Earnout periods run from Jan 1, 2023 through Dec 31, 2024.
Per Repligen's 10-K, FlexBiosys offers expert design of custom single-use bioprocessing products, strengthening the fluid-management portfolio.
Custom single-use product design capability. Strengthens fluid-management portfolio. Repligen Fluid Management
On April 17, 2023, we completed the acquisition of all of the outstanding equity interests in FlexBiosys. FlexBiosys, which is headquartered in Branchburg, New Jersey, offers expert design of custom manufacturing of single-use bioprocessing products.Repligen FY23 10-K, 2023 Acquisitions note
Advisory firms were not disclosed for this transaction.